secwatch.observer — SEC 8-K summary
======================================

Issuer:     Revolution Medicines, Inc. (RVMD)
CIK:        0001628171
Form:       8-K
Filed at:   2025-11-05T23:59:59+00:00
Accession:  0001193125-25-266836
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Revolution Medicines Q3 net loss $305.2M; advancing daraxonrasib pivotal trials
-------------------------------------------------------------------------------

- Net loss $305.2M vs $156.3M YoY; R&D expense $262.5M (+73%), G&A $52.8M (+120%).
- Cash, equivalents & securities $1.93B; full-year GAAP net loss guidance reaffirmed at $1.03B-$1.09B.
- RASolute 302 (PDAC) enrollment winding down; data readout on track for 2026.
- RASolute 304 (adjuvant PDAC) initiated; RASolute 303 (1L metastatic PDAC) expected to start this year.
- New CDO Alan Sandler, U.S. GM Alicia Gardner, Europe GM Gerwin Winter appointed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1628171/000119312525266836/0001193125-25-266836-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1628171/000119312525266836/rvmd-20251105.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-266836

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer